Eli Lilly slips after slashing full-year guidance
Eli Lilly slipped in premarket trading after it beat Wall Street estimates but cut its profit guidance for the year.
The company reported adjusted earnings per share of $3.34, compared to the $3.26 analysts polled by FactSet were expecting. The company reported $12.7 billion in sales, slightly higher than the $12.6 billion analysts were expecting. Sales of its two blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound, were in line with analyst estimates, too.
But the company also lowered its earnings outlook for 2025, which it attributed to higher-than-expected research costs. Management now expects annual adjusted earnings per share of $20.78 to $22.28, down from $22.50 to $24.